Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
PTPRC
REST API REST API
Homo sapiens
PTPRC is differentially expressed in 300 experiments: 144 organism parts: thymus, lung, ... (142 more);, 312 disease states: normal, control, ... (310 more);, 122 cell types 416 cell lines 29 compound treatments and 73 other conditions.
Synonyms LCA, CD45, GP180, T200
Orthologs ptprc (Danio rerio)   PTPRC (Bos taurus)   PTPRC (Gallus gallus)   Ptprc (Rattus norvegicus)   Ptprc (Mus musculus)   ENSCING00000006783 (Ciona intestinalis)   ptprc (Xenopus laevis)   PTPRC (Canis familiaris)   (Compare orthologs)
Gene Ontology Term focal adhesion, defense response to virus, plasma membrane, phosphatase activity, regulation of S phase, protein binding, negative regulation of peptidyl-tyrosine phosphorylation, negative regulation of protein kinase activity, heparin binding, dephosphorylation, heparan sulfate proteoglycan binding, membrane raft, positive regulation of apoptosis, external side of plasma membrane, activation of MAPK activity, positive regulation of protein kinase activity, protein tyrosine phosphatase activity, axon guidance, regulation of cell cycle, cell surface receptor linked signaling pathway, protein kinase binding, integral to plasma membrane, receptor activity, integral to membrane, hydrolase activity, cell surface, response to gamma radiation, release of sequestered calcium ion into cytosol, regulation of apoptosis, positive regulation of alpha-beta T cell proliferation, negative regulation of cytokine-mediated signaling pathway, B cell differentiation, T cell receptor signaling pathway, positive regulation of B cell proliferation, regulation of B cell differentiation, B cell receptor signaling pathway, negative thymic T cell selection, B cell proliferation, peptidyl-tyrosine dephosphorylation, positive regulation of T cell mediated immunity, positive regulation of humoral immune response mediated by circulating immunoglobulin, positive regulation of gamma-delta T cell differentiation, T cell proliferation, immunoglobulin biosynthetic process, heterotypic cell-cell adhesion, regulation of B cell receptor signaling pathway, positive regulation of T cell mediated cytotoxicity, positive regulation of isotype switching to IgG isotypes, positive regulation of T cell differentiation, leukocyte cell-cell adhesion, positive regulation of T cell proliferation, transmembrane receptor protein tyrosine phosphatase activity, positive regulation of MAPKKK cascade, T cell differentiation, positive thymic T cell selection, positive regulation of antigen receptor-mediated signaling pathway, negative regulation of T cell mediated cytotoxicity, regulation of humoral immune response mediated by circulating immunoglobulin, protein dephosphorylation, negative regulation of protein autophosphorylation
InterPro Term Tyr_Pase_cat, Tyr_Pase_rcpt/non-rcpt, Tyr/Dual-specificity_Pase, Fibronectin_type3, Leukocyte_common_ag, PTP_recept_N
UniProt Accession Q9H3X6, Q0VAE8, Q6LDN6, Q6QIN9, Q6QIN1, Q6QIM3, Q6QIR3, Q6QIQ5, Q5T9L9, Q5T9M3, Q5T9M5, Q5T9M0, Q5T9M2, P08575, B1ALS1, B1ALS2, B1ALS3, F5GZM5, E9PMF7, E9PMF8, E9PMG0, E9PPL9, F5GXZ3, Q6Q1P2, E9PC28, E9PKH0, F5H547
Gene-Disease Assocation SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE,, HEPATITIS C VIRUS, SUSCEPTIBILITY TO, MULTIPLE SCLEROSIS, SUSCEPTIBILITY TO; MS
Search EB-eye ENSG00000081237
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, E-GEOD-7224, ... (29 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-19639, E-GEOD-2450, E-GEOD-4342, E-MTAB-62, ... (29 experiments)

Factor Value U/D Experiments
HL-60
3
E-GEOD-5258, E-MTAB-37, E-GEOD-24147
Jurkat
3
E-GEOD-1880, E-MEXP-2197, E-MTAB-62
HepG2
2
E-MTAB-37, E-GEOD-7307
MOLT4
2
E-MTAB-37, E-MTAB-62
SR
2
E-MTAB-37, E-MTAB-62
SW480
2
E-MEXP-1014, E-MTAB-37
410 more value(s).


Cell type

studied in E-GEOD-3920, E-MEXP-750, E-GEOD-20677, E-GEOD-2822, E-GEOD-21909, ... (52 experiments)

Factor Value U/D Experiments
CD14+ monocyte
2
E-AFMX-5, E-TABM-145
CD33+ myeloid
2
E-AFMX-5, E-TABM-145
CD56+ NK cells
2
E-AFMX-5, E-TABM-145
fibroblast
2
E-GEOD-3204, E-GEOD-3920
macrophage
2
E-GEOD-22373, E-GEOD-3982
whole blood
2
E-GEOD-3026, E-MTAB-25
116 more value(s).


Disease state

studied in E-GEOD-3307, E-MEXP-1121, E-GEOD-1577, E-TABM-15, E-MEXP-2280, ... (82 experiments)

Factor Value U/D Experiments
prostate carcinoma
4
E-GEOD-96, E-MTAB-62, E-MTAB-37, E-MEXP-2034
acute promyelocytic leukemia
3
E-MTAB-62, E-GEOD-995, E-GEOD-96
lung adenocarcinoma
1
3
E-MTAB-37, E-MTAB-62, E-GEOD-2514, E-MEXP-231
chronic myelogenous leukemia
1
3
E-MTAB-62, E-MTAB-37, E-GEOD-96, E-GEOD-5550
ischemic cardiomyopathy
2
E-GEOD-1145, E-MTAB-62
AIDS-KS, HIV+, nodular (late) stage
1
2
E-MEXP-66, E-MTAB-62
306 more value(s).


Compound treatment

studied in E-GEOD-15205, E-TABM-782, E-GEOD-3720, E-GEOD-5824, E-TABM-868, ... (22 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
TGF
1
1
E-GEOD-15205
ethanol
1
E-MEXP-2241
eicosapentaenoic acid
1
E-MEXP-1389
interferon-gamma
1
E-GEOD-1925
Cxcl12
1
1
E-GEOD-7307
23 more value(s).


Age at diagnosis

studied in E-GEOD-21653, E-GEOD-4922

Factor Value U/D Experiments
47
2
1
E-GEOD-21653
72
2
1
E-GEOD-21653
71
2
1
E-GEOD-21653
72 years
1
1
E-GEOD-4922


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37, E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Chromosomal aberration
studied in E-TABM-125

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-21374, ... (11 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-GEOD-6236, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-MTAB-69, E-GEOD-22148, E-TABM-147, ... (8 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-17385

Genotype
studied in E-TABM-763, E-GEOD-3494, E-GEOD-17476, E-TABM-321, E-TABM-868, ... (7 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-GEOD-7011, E-GEOD-12773, E-TABM-127, ... (12 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-2069, E-GEOD-1926, ... (40 experiments)

individual id
studied in E-GEOD-19519

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-MEXP-561, E-GEOD-17400

Injury
studied in E-GEOD-19743

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Organism
studied in E-GEOD-2634, E-GEOD-7540, E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-19703, E-GEOD-1309, E-GEOD-22309, E-GEOD-21750, ... (7 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-MEXP-101, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886

stimulus
studied in E-GEOD-22103

Survival time
studied in E-GEOD-4922, E-GEOD-19188

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-33562, E-GEOD-22368, E-GEOD-22152, E-GEOD-16837, ... (8 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-22541, E-GEOD-4922

Tumor size
studied in E-GEOD-3494

Processing time: 0.397 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM